Growth Metrics

Rxo (RXO) Liabilities and Shareholders Equity (2021 - 2025)

Rxo (RXO) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $3.2 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 5.63% year-over-year to $3.2 billion, compared with a TTM value of $9.7 billion through Dec 2025, down 6.83%, and an annual FY2024 reading of $3.4 billion, up 87.07% over the prior year.
  • Liabilities and Shareholders Equity was $3.2 billion for Q3 2025 at Rxo, roughly flat from $3.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $3.4 billion in Q4 2024 and bottomed at $1.8 billion in Q1 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $2.4 billion, with a median of $2.0 billion recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity dropped 13.01% in 2023, then skyrocketed 87.07% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $2.1 billion in 2021, then fell by 1.79% to $2.0 billion in 2022, then fell by 10.14% to $1.8 billion in 2023, then surged by 87.07% to $3.4 billion in 2024, then dropped by 6.24% to $3.2 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for RXO at $3.2 billion in Q3 2025, $3.2 billion in Q2 2025, and $3.3 billion in Q1 2025.